Express Healthcare
Home  »  Cardiac Care  »  Innovative imaging technology promises improved cardiac care

Innovative imaging technology promises improved cardiac care

0 183
Read Article

Leading global  experts in interventional cardiology recently participated and shared their breaking clinical trials, researches, latest evidence-based medicine, latest technologies and innovations iat the 32nd global annual scientific symposium, Transcatheter Cardiovascular Therapeutics

Increasing cardiovascular burden globally and the need for innovative technologies has changed the face of heart care today. With the changing lifestyles and the current pandemic leaving an impact on the heart, the situation has become more complex. This has led cardiologists to push the envelope and find new ways to treat patients. Leading experts from the various fields of interventional cardiology from across the globe including scientists, radiologists, clinical cardiologists, vascular medicine specialists, cardiac and vascular surgeons recently participated and shared their breaking clinical trials, researches, latest evidence-based medicine, latest technologies and innovations in the field of intervention at the 32nd global annual scientific symposium, Transcatheter Cardiovascular Therapeutics.

One of the key topics discussed at the global platform was the result of clinical trial on imaging iOPTICO from India. iOPTICO is based on Optical Coherence Tomography (OCT), the latest imaging technology in the field of coronary intervention. For many years, angiography has been the medium of guidance for percutaneous coronary interventions (PCI) but could only provide limited information of the diseased coronary arteries. But, the latest imaging technology, OCT comes with an enhanced visualisation and high-resolution imaging, which helps in accurate decision making, strategising the procedure precisely and optimise the outcome, thus leading to a PRECESION PCI with better patient outcomes.

The trial involved 500 patients, who were enrolled between November 2018 to March 2020 from nine locations across India and Bangladesh. The patients were selected for the study, if they had significant coronary artery stenosis (diameter stenosis >70 per cent based on visual assessment on the coronary angiogram) in at least one native coronary artery after angiography. The primary objective was to assess the change in treatment strategy pre and post PCI (percutaneous coronary intervention). Pre-PCI strategy change involved need for lesion preparation, change in the intended stent length and size, and intended device landing zone. Post-PCI strategy change involved the intended need for additional interventional procedures for PCI optimisation after identification of stent malaposition, edge dissections, and stent under expansion. This was the first South Asian study reporting the outcomes of OCT-ACR (Angiographic co-registered) guided PCI in patients with coronary artery disease.

The key findings of the study were that when OCT was used along with angiography, it changed the angiographic based decisions in 90 per cent of the lesions in the patients who underwent the trial. Cardiologists changed their strategy in 86 per cent of lesions before PCI and 30 per cent of lesions after PCI.

The primary investigator (PI) of iOPTICO, Dr. Rony Mathew (HOD & Senior Consultant, Lisie Cardiology Dept) shed light on the technology and said, “OCT is the new approach to PCI procedure as it helps an operator see better and get all the information inside the diseased coronary artery. In this study, when OCT was used along with angiography, it changed the angiographic based decision in 90 per cent of the lesions in trial patients. It enhances decision making through precision and accuracy.”

Referring to a recently presented US clinical trial LightLab data, site investigator of the trial Dr. Balbir Singh, Chairman and Head, Cardiology for Max Healthcare group highlighted, “The field of Interventional cardiology is getting more advanced and is culminating towards perfection or PRECESION PCI and both Indian iOPTICO and US LightLab data shows similar change in the PCI strategy in spite of varied demography and clinical setup. The LightLab data has shown a cumulative impact of decision change with OCT on 88 per cent of the lesions, with pre-PCI OCT impact of 83 per cent and post-PCI OCT impact of 31 per cent of the lesions in the study patients compared to angiography.”

Another site investigator Dr Samuel Mathew, Director – Cardiac Cath Lab, Apollo Hospitals, Chennai (Chief consultant & Lilavati Hospital) who is known as the pioneer and Father of Angioplasty in India emphasised, “Intravascular imaging (IVI) guided percutaneous coronary intervention (PCI) has shown to be associated with superior outcomes compared to angiography-based PCI. Optical coherence tomography (OCT) is a high-resolution IVI modality used widely for PCI optimisation. The current iOPTICO study was designed to evaluate the utility newer angiography – OCT co-registration (ACR) workflow in PCI optimisation in a population of 500 Indian patients. This first South Asian study iOPTICO will open up new dimensions in the field of intervention cardiology and will solely benefit the patients with coronary artery disease as cardiologists will see with clarity and treat with certainty leading to excellent clinical outcome.”

Other investigators from India and Bangladesh included eminent cardiologists such as Dr. Jabir A, Senior Consultant and Director of Clinical Research (Cardiology) at Lisie Cardiology Dept, Dr. Tejas Patel, Chairman and Chief Interventional Cardiologist at Apex Heart Institute, Dr. Balbir Singh, Chairman N Head, Cardiology at Max Healthcare, Dr. Nagendra SC, Director – Department of Interventional Cardiology in Medanta-The Medicity, Gurugram, Prof Fazila-Tun-Nesa Malik Cardiology Specialist at National Heart Foundation Hospital and Research Institute, Dhaka, Dr. Shirish (M.S) Hiremath, Director, Cathlab, Ruby Hall Pune, Dr. G. Sengottuvelu-Senior Consultant and Interventional Cardiologist at Apollo Hospitals, Chennai, Dr. Samuel Mathew, Chief Interventional Cardiologist, Apollo Hospital Chennai and Lilavati Hospital and Research Centre, Mumbai, Dr. Viveka Kumar, Principal Director & Chief of Cath Labs, Max Healthcare, Dr. Vijayakumar, Cardiologist at The Madras Medical Mission Hospital and Dr. Shivakumar, Senior Consultant Cardiologist at Meenakshi Mission Hospital & Research Centre (MMHRC) Madurai;  for their continuous support and efforts for making this clinical trial successful.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?